Showing results (251-260 of 771) with videos related to
Sort By:
Pageof 78
The Journal of Medical Practice Management : MPM|May 15, 2007
What patients want: A content analysis of key qualities that influence patient satisfactionRoger Anderson, Angela Barbara, Steven FeldmanJournal of Drugs in Dermatology : JDD|July 11, 2022
Adherence and Persistence to Acne Medications: A Population-Based Claims Database AnalysisAyman Grada, Patrick Perche, Steven FeldmanJournal of Drugs in Dermatology : JDD|April 7, 2022
A Case of Late-Onset Alopecia AreataPaul Macklis, Caroline Porter, Steven FeldmanDermatology and Therapy|November 18, 2019
Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe PsoriasisElsie Grace, Orin Goldblum, Lisa Renda, et al.Journal of the American Academy of Dermatology|February 11, 2011
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions, Alan Menter, Neil J Korman, et al.Current Medical Research and Opinion|September 14, 2010
Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trialArthur Kavanaugh, Alan Menter, Alan Mendelsohn, et al.Journal of the American Academy of Dermatology|May 22, 2004
A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasisChristopher S Carlin, Steven R Feldman, James G Krueger, et al.International Journal of Dermatology|March 26, 2003
Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacyNick J Lowe, John Gonzalez, Jerry Bagel, et al.Dermatologic Therapy|November 2, 2020
Ixekizumab in the treatment of moderate-to-severe plaque psoriasis: Patient adherence, satisfaction, and preferencesAaminah Azhar, Marcus Zaayman, Annika Silfvast-Kaiser, et al.Lancet (London, England)|June 15, 2015
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trialsChristopher E M Griffiths, Kristian Reich, Mark Lebwohl, et al.Pageof 78